** Cancer-related drugmaker Telix Pharmaceuticals Ltd
TLX.AX fall as much as 15.7% to A$6.82, marks its worst
intraday session since Sept 23
** Co announces https://telixpharma.com/investors placement
of 22.7 mln shares at A$7.70 apiece to raise A$175 mln ($125.65
mln)
** Issue price represents a discount of 4.8% to TLX's close
of A$8.09 on Jan 19, stock was on a trading halt since Jan 20
** Says will use funds to execute its late-stage clinical
product pipeline and advance its multiple program towards
commercialisation
** Newly issued shares represent about 13% of co's free
float of 176.2 mln shares, according to Refinitiv data
** TLX hits lowest level since Dec 7
** More than 5.6 mln shares change hands, vs the 30-day
average of 610,600 shares
** TLX up 4.4% this year, as of last close
($1 = 1.3928 Australian dollars)
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com; Twitter: https://twitter.com/sameer_manekar))